Bimatoprost in the Treatment of Eyelash Hypotrichosis

    April 2010 in “ PubMed Central ”
    Simon K. Law
    Studysummary This abstract discusses the FDA approval of Latisse (bimatoprost) for increasing eyelash growth in patients with eyelash hypotrichosis and highlights its efficacy while noting unresolved effectiveness in certain conditions and potential side effects.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Related research 7

    1. Therapeutic Potential of Bimatoprost for the Treatment of Eyebrow Hypotrichosis Drug Design Development and Therapy · 2018
    2. Bimatoprost for the Treatment of Eyelash, Eyebrow, and Scalp Alopecia Expert Opinion on Investigational Drugs · 2017
    3. Bimatoprost Solution 0.03% Topical Application to the Eyelid Margin for the Treatment of Eyelash Hypotrichosis British Journal of Dermatology · 2016
    4. Long-Term Safety and Efficacy of Latisse (Bimatoprost 0.03% Solution) for Treatment of Eyelash Hypotrichosis in Subjects with Chemotherapy-Induced and Idiopathic Hypotrichosis Journal of The American Academy of Dermatology · 2012
    5. Lack of Efficacy of Topical Latanoprost and Bimatoprost Ophthalmic Solutions in Promoting Eyelash Growth in Patients with Alopecia Areata Yearbook of Dermatology and Dermatologic Surgery · 2010
    6. Instilled Bimatoprost Ophthalmic Solution in Patients with Eyelash Alopecia Areata Journal of the American Academy of Dermatology · 2009
    7. Lack of Efficacy of Topical Latanoprost and Bimatoprost Ophthalmic Solutions in Promoting Eyelash Growth in Patients with Alopecia Areata Journal of The American Academy of Dermatology · 2009